We Claim :

1. A compound of the formula:



(I-1)

wherein,

A ring is optionally substituted heterocycle;

R^{14} and R^X are independently hydrogen, optionally substituted C_1-C_{10} alkyl, optionally substituted C_3-C_8 cycloalkyl, optionally substituted C_3-C_8 cycloalkyl C_1-C_{10} alkyl, optionally substituted C_2-C_8 alkenyl, optionally substituted C_1-C_{10} alkoxy, optionally substituted C_2-C_8 alkenyloxy, optionally substituted aryl, optionally substituted aryl C_1-C_{10} alkyl, optionally substituted aryloxy, optionally substituted heterocyclic group, optionally substituted heterocycle C_1-C_{10} alkyl, optionally substituted heterocycleoxy, optionally substituted phosphoric acid residue, aryl substituted with optionally substituted phosphoric acid residue, aralkyl substituted with optionally substituted phosphoric acid residue, hydroxy substituted with optionally substituted phosphoric acid residue, amino substituted with optionally substituted phosphoric acid residue or C_1-C_{10} alkyl substituted with optionally substituted phosphoric acid residue (the C_1-C_{10} alkyl may be intervened by a heteroatom group selected from O, S, SO, SO_2, NR^5, R^5 being selected independently from the same substituent group as R^4), -N= and =N-), hydroxy, optionally substituted amino, optionally substituted C_1-C_{10} alkyl carbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted C_3-C_8 cycloalkyl C_1-C_{10} alkyl carbonyl, optionally substituted C_1-C_{10} alkoxy carbonyl, optionally substituted arylcarbonyl, optionally substituted aryl C_1-C_{10} alkyl carbonyl, optionally substituted aryloxycarbonyl, optionally substituted heterocyclecarbonyl, optionally substituted heterocycle C_1-C_{10} alkyl carbonyl, optionally substituted heterocycleoxy carbonyl or optionally substituted aminocarbonyl;

a broken line represents the presence or absence of a bond, provided that when the broken line represents the presence of a bond, R^X is not present;

R^1 is hydrogen or C_1-C_{10} alkyl;

X is a single bond, a heteroatom group selected from O, S, SO, SO_2 and NH, or C_1-C_6 alkylene or C_2-C_6 alkenylene each may be intervened by the heteroatom group;

R^2 is optionally substituted aryl;

R^3 is hydrogen, halogen, hydroxy, optionally substituted C_1-C_{10} alkyl, optionally substituted C_3-C_8 cycloalkyl, optionally substituted C_2-C_8 alkenyl, optionally substituted C_1-C_{10} alkoxy, optionally substituted C_2-C_8 alkenyloxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterocyclic group, optionally substituted heterocycleoxy or optionally substituted amino);

or a pharmaceutically acceptable salt, or solvate thereof;

and wherein:

(a) a group which is optionally substituted, other than optionally substituted amino, optionally substituted carbamoyl or optionally substituted phosphoric acid, is a group which is unsubstituted or substituted at any position by 1 to 4 substituents B, which are the same or different, B being selected from hydroxy, carboxy, halogen, halo C_1-C_{10} alkyl, halo C_1-C_{10} alkoxy, C_1-C_{10} alkyl, C_2-C_8 alkenyl, ethynyl, C_3-C_8 cycloalkyl, cycloalkenyl, C_1-C_{10} alkoxy C_2-C_8 alkenyloxy, C_1-C_{10} alkoxycarbonyl, nitro, nitroso, optionally substituted amino, acylamino, aralkylamino, hydroxyamino, azido, aryl, aralkyl, cyano, isocyano, isocyanate, thiocyanate, isothiocyanate, mercapt, alkylthio, alkylsulfonyl, optionally substituted alkylsulfonylamino, optionally substituted carbamoyl, sulfamoyl, acyl, formyloxy, haloformyl, oxal, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, sulfino, sulfo, sulfoamino, hydrazino, azido, ureido, amizino, quanidino, phthalimide, oxo, phosphoric acid residue, C_1-C_{10} alkyl which is substituted with a phosphoric acid residue and may be intervened with a heteroatom group(s), aryl substituted with a phosphoric acid residue, aralkyl substituted with a phosphoric acid residue, hydroxyl C_1-C_{10} alkyl, carboxy, halogen, halo C_1-C_{10} alkyl, halo C_1-C_{10} alkoxy, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, optionally substituted amino, oxo and phosphoric acid residue;

(b) "optionally substituted amino" or "optionally substituted carbamoyl" means an amino or carbamoyl group which is unsubstituted or substituted by a group selected from mono- or di- C_1-C_{10} alkyl, C_1-C_{10} alkylcarbonyl, C_1-C_{10} alkylsulfonyl, optionally substituted C_1-C_{10} alkyl, carbamoylalkyl, mono- or di- C_1-C_{10} alkylcarbamoyl, C_1-C_{10} alkyl, hydroxyl C_1-C_{10} alkyl, heterocycle C_1-C_{10} alkyl,

C_1-C_{10} alkoxycarbonyl C_1-C_{10} alkyl, mono- or di- C_1-C_{10} alkylamino C_1-C_{10} alkyl, C_1-C_{10} alkoxy C_1-C_{10} alkyl, acyl, C_1-C_{10} alkoxy C_1-C_{10} alkylcarbonyl, C_1-C_{10} alkylcarbamoyl C_1-C_{10} alkylcarbonyl, C_1-C_{10} alkoxycarbonylacetyl, optionally substituted arylcarbonyl, optionally substituted aralkyl, hydroxy, optionally substituted C_1-C_{10} alkylsulfonyl, C_1-C_{10} alkyl, or arylsulfonyl optionally substituted with halogen, C_3-C_8 cycloalkyl, aryl optionally substituted

with C_1-C_{10} alkyl, C_1-C_{10} alkylaminosulfonyl, C_1-C_{10} alkylaminocarbonyl, C_1-C_{10} alkoxycarbonyl, C_3-C_8 cycloalkylcarbonyl, optionally substituted sulfamoyl, C_1-C_{10} alkylcarbonylamino, heterocycle, and optionally substituted amino, and wherein, as to the amino of "optionally substituted amino", "optionally substituted carbamoyl", or "optionally substituted carbamoylcarbonyl", two substituents on the amino together with the neighboring N atom may form an N-containing heterocycle which optionally contains S and/or O in the ring and is optionally substituted with oxo or hydroxy; and

(c) an optionally substituted phosphoric acid residue is a group of the formula:

$-PO(OH)_2$ wherein the OH part and/or a hydrogen of the OH is optionally substituted with a phosphoric acid residue of the formula:



(P-1)

wherein, R^A and R^B each is independently OR^C or NR^DR^E (wherein R^C, R^D and R^E are each independently hydrogen, optionally substituted C_1-C_{10} alkyl, optionally substituted C_3-C_8 cycloalkyl, optionally substituted aryl, optionally substituted heterocyclic group, or R^D and R^E taken together with the neighboring N atom may form an optionally substituted heterocycle, or R^A and R^B taken together with the neighboring P atom may form an optionally substituted heterocycle).

2. A compound as claimed in Claim 1, pharmaceutically acceptable salt, or solvate thereof, wherein R^1 is hydrogen or C_1-C_{10} alkyl; X is C_1-C_6 alkylene; R^2 is phenyl or phenyl substituted with at least halogen; R^3 is hydrogen, halogen, hydroxy, C_1-C_{10} alkyl, C_2-C_8 alkenyl, C_1-C_{10} alkoxy, C_1-C_{10} alkenyloxy or optionally substituted amino.

3. A compound as claimed in Claim 1, pharmaceutically acceptable salt, or solvate thereof, wherein a broken line represents the absence of a bond.

4. A compound as claimed in Claim 1, pharmaceutically acceptable salt, or solvate thereof, wherein R^X is hydrogen; R^{14} is hydrogen or optionally substituted C_1-C_{10} alkyl.

5. A compound as claimed in Claim 1, pharmaceutically acceptable salt, or solvate thereof, wherein A ring is an optionally substituted and optionally condensed 5- to 7- membered heterocycle containing 1 to 2 hetero atom(s).

6. A compound of the formula:



(I-1-1)

wherein,

A ring is an optionally substituted and optionally condensed 5- to 7- membered heterocycle containing 1 to 2 hetero atom(s);

the stereochemistry of an asymmetric carbon represented by * shows R- or S-configuration, or a mixture thereof;

R^{14} and R^X are independently hydrogen, optionally substituted C_1-C_{10} alkyl, optionally substituted C_3-C_8 cycloalkyl, optionally substituted C_3-C_8 cycloalkyl C_1-C_{10} alkyl, optionally substituted C_2-C_8 alkenyl, optionally substituted C_1-C_{10} alkoxy, optionally substituted C_2-C_8 alkenyloxy, optionally substituted aryl, optionally substituted aryl C_1-C_{10} alkyl, optionally substituted aryloxy, optionally substituted heterocyclic group, optionally substituted heterocycle C_1-C_{10} alkyl, optionally substituted heterocycleoxy, optionally substituted phosphoric acid residue, aryl substituted with optionally substituted phosphoric acid residue, aralkyl substituted with optionally substituted phosphoric acid residue, hydroxy substituted with optionally substituted phosphoric acid residue, amino substituted with optionally substituted phosphoric acid residue or C_1-C_{10} alkyl substituted with optionally substituted phosphoric acid residue (the C_1-C_{10} alkyl may be intervened by a heteroatom group selected from O, S, SO, SO_2, NR^5 (R^5 being selected independently from the same substituent group as R^4), -N= and =N-), hydroxy, optionally substituted amino, optionally substituted C_1-C_{10} alkyl carbonyl, optionally substituted C_3-C_8 cycloalkylcarbonyl, optionally substituted C_3-C_8 cycloalkyl C_1-C_{10} alkyl carbonyl, optionally substituted C_1-C_{10} alkoxy carbonyl, optionally substituted arylcarbonyl, optionally substituted aryl C_1-C_{10} alkyl carbonyl, optionally substituted aryloxycarbonyl, optionally substituted heterocyclecarbonyl, optionally substituted heterocycle C_1-C_{10} alkyl carbonyl, optionally substituted heterocycleoxy carbonyl or optionally substituted aminocarbonyl;

R^3 is hydrogen, halogen, hydroxy, optionally substituted C_1-C_{10} alkyl, optionally substituted C_3-C_8 cycloalkyl, optionally substituted C_2-C_8 alkenyl, optionally substituted C_1-C_{10} alkoxy, optionally substituted C_2-C_8 alkenyloxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterocyclic group, optionally substituted heterocycleoxy or optionally substituted amino), its pharmaceutically acceptable salt, or

R^1 is hydrogen or C_1-C_{10} alkyl;

R is independently selected from halogen and Substituent group S1;

substituent group S1 is selected from: optionally substituted phosphoric acid residue, aryl substituted with optionally substituted phosphoric acid residue, aralkyl substituted with optionally substituted phosphoric acid residue, hydroxy substituted with optionally substituted phosphoric acid residue, amino substituted with optionally substituted phosphoric acid residue, or C_1-C_{10} alkyl substituted with optionally substituted phosphoric acid residue (wherein the C_1-C_{10} alkyl may be intervened with a heteroatom group(s) selected from CO, O, O, S, SO, SO_2, NR^a (R^a is hydrogen or C_1-C_{10} alkyl), -N= and =N-), C_1-C_{10} alkoxy C_1-C_{10} alkyl, amino C_1-C_{10} alkyl optionally substituted with mono- or di- C_1-C_{10} alkyl, halogenated C_1-C_{10} alkyl, C_1-C_{10} alkoxy, carbamoyl optionally substituted with mono- or di- C_1-C_{10} alkyl, optionally substituted C_1-C_{10} alkyl sulfonyl amino, halogenated C_1-C_{10} alkoxy and hydroxy C_1-C_{10} alkyl; and

m is an integer of 0 to 3;

or a pharmaceutically acceptable salt, or solvate thereof,

and wherein :

(a) a group which is optionally substituted, other than optionally substituted amino, optionally substituted carbamoyl or optionally substituted phosphoric acid, is a group which is unsubstituted or substituted at any position by 1 to 4 substituents B, which are the same or different, B being selected from hydroxy, carboxy, halogen, halo C_1-C_{10} alkyl, halo C_1-C_{10} alkoxy, C_1-C_{10} alkyl, C_2-C_8 alkenyl, ethynyl, C_3-C_8 cycloalkyl, cycloalkenyl, C_1-C_{10} alkoxy C_2-C_8 alkenyloxy, C_1-C_{10} alkoxycarbonyl, nitro, nitroso, optionally substituted amino, acylamino, aralkylamino, hydroxyamino, azido, aryl, aralkyl, cyano, isocyano, isocyanate, thiocyanate, isothiocyanate, mercapt, alkylthio, alkylsulfonyl, optionally substituted alkylsulfonylamino, optionally substituted carbamoyl, sulfamoyl, acyl, formyloxy, haloformyl, oxal, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, sulfino, sulfo, sulfoamino, hydrazino, azido, ureido, amizino, quanidino, phthalimide, oxo, phosphoric acid residue, C_1-C_{10} alkyl which is substituted with a phosphoric acid residue and may be intervened with a heteroatom group(s), aryl substituted with a phosphoric acid residue, aralkyl substituted with a

phosphoric acid residue, hydroxyl C_1-C_{10} alkyl, carboxy, halogen, halo C_1-C_{10} alkyl, halo C_1-C_{10} alkoxy, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, optionally substituted amino, oxo and phosphoric acid residue;

(b) "optionally substituted amino" or "optionally substituted carbamoyl" means an amino or carbamoyl group which is unsubstituted or substituted by a group selected from mono- or di- C_1-C_{10} alkyl, C_1-C_{10} alkylcarbonyl, C_1-C_{10} alkylsulfonyl, optionally substituted C_1-C_{10} alkyl, carbamoylalkyl, mono- or di- C_1-C_{10} alkylcarbamoyl, C_1-C_{10} alkyl, hydroxyl C_1-C_{10} alkyl, heterocycle C_1-C_{10} alkyl, C_1-C_{10} alkoxycarbonyl C_1-C_{10} alkyl, mono- or di- C_1-C_{10} alkylamino C_1-C_{10} alkyl, C_1-C_{10} alkoxy C_1-C_{10} alkyl, acyl, C_1-C_{10} alkoxy C_1-C_{10} alkylcarbonyl, C_1-C_{10} alkylcarbamoyl C_1-C_{10} alkylcarbonyl, C_1-C_{10} alkoxycarbonylacetyl, optionally substituted arylcarbonyl, optionally substituted aralkyl, hydroxy, optionally substituted C_1-C_{10} alkylsulfonyl, C_1-C_{10} alkyl, or arylsulfonyl optionally substituted with halogen, C_3-C_8 cycloalkyl, aryl optionally substituted with C_1-C_{10} alkyl, C_1-C_{10} alkylaminosulfonyl, C_1-C_{10} alkylaminocarbonyl, C_1-C_{10} alkoxycarbonyl, C_3-C_8 cycloalkylcarbonyl, optionally substituted sulfamoyl, C_1-C_{10} alkylcarbonylamino, heterocycle, and optionally substituted amino, and wherein, as to the amino of "optionally substituted amino", "optionally substituted carbamoyl", or "optionally substituted carbamoylcarbonyl", two substituents on the amino together with the neighboring N atom may form an N-containing heterocycle which optionally contains S and/or O in the ring and is optionally substituted with oxo or hydroxy; and

(c) an optionally substituted phosphoric acid residue is a group of the formula:

$-PO(OH)_2$ wherein the OH part and/or a hydrogen of the OH is optionally substituted with a phosphoric acid residue of the formula:



(P-1)

wherein, R^A and R^B each is independently OR^C or NR^DR^E (wherein R^C, R^D and R^E are each independently hydrogen, optionally substituted C_1-C_{10} alkyl, optionally substituted C_3-C_8 cycloalkyl, optionally substituted aryl, optionally substituted heterocyclic group, or R^D and R^E taken together with the neighboring N atom may form an optionally substituted heterocycle, or R^A and R^B taken together with the neighboring P atom may form an optionally substituted heterocycle).

7. A compound as claimed in Claim 6, pharmaceutically acceptable salt, or solvate thereof, wherein R^X and R^{14} are independently hydrogen or optionally substituted C_1-C_{10} alkyl.

8. A compound as claimed in Claim 6, pharmaceutically acceptable salt, or solvate thereof, wherein R^X and R^{14} are hydrogens.

9. A compound as claimed in Claim 6, pharmaceutically acceptable salt, or solvate thereof, wherein R^3 is hydrogen.

10. A compound as claimed in Claim 6, pharmaceutically acceptable salt, or solvate thereof, wherein m is 0, or 1 to 3 and at least one of R is halogen.

11. A compound as claimed in Claim 1 or 6, pharmaceutically acceptable salt, or solvate thereof, wherein A ring is any one of the followings:



Z = O or NR^{26}

(A-1)



Z = O or NR^{31}

(A-2)



Z = O or NR^{40}

(A-3)

wherein R^{20} to R^{40} are each independently a group selected from substituent group S2, or any two groups of R^{20} to R^{40}, which bonds to the same carbon atom, taken together with the carbon atom, may form an optionally substituted carbocyle or optionally substituted heterocycle, or each combination of (R^{20} and R^{22}), (R^{23} and R^{24}), (R^{25} and R^{26}), (R^{27} and R^{29}), (R^{30} and R^{31}), (R^{32} and R^{34}), (R^{35} and R^{36}), (R^{37} and R^{38}), and ($R^{39}$and R^{40}), taken together with the neighboring atom, may form an optionally substituted carbocyle or optionally substituted heterocycle; and substituent group S2 is selected from hydrogen, optionally substituted C_1-C_{10} alkyl, optionally substituted C_3-C_8 cycloalkyl, optionally substituted C_3-C_8 cycloalkyl C_1-C_{10} alkyl, optionally substituted C_2-C_8 alkenyl, optionally substituted C_1-C_{10} alkoxy, optionally substituted C_2-C_8 alkenyloxy, optionally substituted aryl, optionally

substituted aryl C_1-C_{10} alkyl, optionally substituted aryloxy, optionally substituted heterocycle, optionally substituted heterocycle C_1-C_{10} alkyl, optionally substituted heterocycleoxy, hydroxy, optionally substituted amino, optionally substituted C_1-C_{10} alkylcarbonyl, optionally substituted C_3-C_8 cycloalkylcarbonyl, optionally substituted C_3-C_8 cycloalkyl C_1-C_{10} alkylcarbonyl, optionally substituted C_1-C_{10} alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryl C_1-C_{10} alkylcarbonyl, optionally substituted aryl oxycarbonyl, optionally substituted heterocyclecarbonyl, optionally substituted heterocycle C_1-C_{10} alkylcarbonyl, optionally substituted heterocycleoxycarbonyl, optionally substituted aminocarbonyl, optionally substituted phosphoric acid residue, aryl substituted with optionally substituted phosphoric acid residue, aralkyl substituted with optionally substituted phosphoric acid residue, hydroxy substituted with optionally substituted phosphoric acid residue, amino substituted with optionally substituted phosphoric acid residue, or C_1-C_{10} alkyl substituted with optionally substituted phosphoric acid residue (the C_1-C_{10} alkyl may be intervened with a heteroatom group(s) selected from CO, O, S, SO, SO_2, NR^5 in which R^5 is independently selected from the same substituent group as R^4, -N= and =N-);

the stereochemistry of an asymmetric carbon represented by * shows R- or S-configuration, or a mixture thereof;

and wherein :

(a) a group which is optionally substituted, other than optionally substituted amino, optionally substituted carbamoyl or optionally substituted phosphoric acid, is a group which is unsubstituted or substituted at any position by 1 to 4 substituents B, which are the same or different, B being selected from hydroxy, carboxy, halogen, halo C_1-C_{10} alkyl, halo C_1-C_{10} alkoxy, C_1-C_{10} alkyl, C_2-C_8 alkenyl, ethynyl, C_3-C_8 cycloalkyl, cycloalkenyl, C_1-C_{10} alkoxy C_2-C_8 alkenyloxy, C_1-C_{10} alkoxycarbonyl, nitro, nitroso, optionally substituted amino, acylamino, aralkylamino, hydroxyamino, azido, aryl, aralkyl, cyano, isocyano, isocyanate, thiocyanate, isothiocyanate, mercapt, alkylthio, alkylsulfonyl, optionally substituted alkylsulfonylamino, optionally substituted carbamoyl, sulfamoyl, acyl, formyloxy, haloformyl, oxal, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, sulfino, sulfo, sulfoamino, hydrazino, azido, ureido, amizino, quanidino, phthalimide, oxo, phosphoric acid residue, C_1-C_{10} alkyl which is substituted with a phosphoric acid residue and may be intervened with a heteroatom group(s), aryl substituted with a phosphoric acid residue, aralkyl substituted with a phosphoric acid residue, hydroxyl C_1-C_{10} alkyl, carboxy, halogen, halo C_1-C_{10} alkyl, halo C_1-

C_{10} alkoxy, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, optionally substituted amino, oxo and phosphoric acid residue;

(b) "optionally substituted amino" or "optionally substituted carbamoyl" means an amino or carbamoyl group which is unsubstituted or substituted by a group selected from mono- or di- C_1-C_{10} alkyl, C_1-C_{10} alkylcarbonyl, C_1-C_{10} alkylsulfonyl, optionally substituted C_1-C_{10} alkyl, carbamoylalkyl, mono- or di- C_1-C_{10} alkylcarbamoyl, C_1-C_{10} alkyl, hydroxyl C_1-C_{10} alkyl, heterocycle C_1-C_{10} alkyl, C_1-C_{10} alkoxycarbonyl C_1-C_{10} alkyl, mono- or di- C_1-C_{10} alkylamino C_1-C_{10} alkyl, C_1-C_{10} alkoxy C_1-C_{10} alkyl, acyl, C_1-C_{10} alkoxy C_1-C_{10} alkylcarbonyl, C_1-C_{10} alkylcarbamoyl C_1-C_{10} alkylcarbonyl, C_1-C_{10} alkoxycarbonylacetyl, optionally substituted arylcarbonyl, optionally substituted aralkyl, hydroxy, optionally substituted C_1-C_{10} alkylsulfonyl, C_1-C_{10} alkyl, or arylsulfonyl optionally substituted with halogen, C_3-C_8 cycloalkyl, aryl optionally substituted with C_1-C_{10} alkyl, C_1-C_{10} alkylaminosulfonyl, C_1-C_{10} alkylaminocarbonyl, C_1-C_{10} alkoxycarbonyl, C_3-C_8 cycloalkylcarbonyl, optionally substituted sulfamoyl, C_1-C_{10} alkylcarbonylamino, heterocycle, and optionally substituted amino, and wherein, as to the amino of "optionally substituted amino", "optionally substituted carbamoyl", or "optionally substituted carbamoylcarbonyl", two substituents on the amino together with the neighboring N atom may form an N-containing heterocycle which optionally contains S and/or O in the ring and is optionally substituted with oxo or hydroxy; and

(c) an optionally substituted phosphoric acid residue is a group of the formula:

$-PO(OH)_2$ wherein the OH part and/or a hydrogen of the OH is optionally substituted with a phosphoric acid residue of the formula:



(P-1)

wherein, R^A and R^B each is independently OR^C or NR^DR^E (wherein R^C, R^D and R^E are each independently hydrogen, optionally substituted C_1-C_{10} alkyl, optionally substituted C_3-C_8 cycloalkyl, optionally substituted aryl, optionally substituted heterocyclic group, or R^D and R^E taken together with the neighboring N atom may form an optionally substituted heterocycle, or R^A and R^B taken together with the neighboring P atom may form an optionally substituted heterocycle).

12. A compound as claimed in Claim 11, pharmaceutically acceptable salt, or solvate thereof, wherein R^{20} to R^{40} are each independently hydrogen or substituted C_1-C_{10} alkyl, or any two groups of R^{20} to R^{40}, which bonds to the same carbon atom, taken together with the carbon atom, may form an optionally substituted 3- to 7- membered carbocyle or optionally substituted 3- to 7- membered heterocycle, or each combination of (R^{20} and R^{22}), (R^{23} and R^{24}), (R^{25} and R^{26}), (R^{27} and R^{29}), (R^{30} and R^{31}), (R^{32} and R^{34}), (R^{35} and R^{36}), (R^{37} and R^{38}), and (R^{39}andR^{40}), taken together with the neighboring atom, may form an optionally substituted 5- to 7- membered carbocyle or optionally substituted 5- to 7- membered heterocycle.

13. A compound as claimed in Claim 11, pharmaceutically acceptable salt, or solvate thereof, wherein A ring is a ring represented by (A-1); one of R^{20} to R^{25} is optionally substituted C_1-C_{10} alkyl and the others are hydrogens.

14. A compound as claimed in Claim 11, pharmaceutically acceptable salt, or solvate thereof, wherein A ring is a ring represented by (A-1); one of (R^{20} and R^{22}), (R^{23} and R^{24}), and (R^{25} and R^{26}), taken together with the neighboring atom, may form an optionally substituted 5- to 7- membered carbocyle or optionally substituted 5- to 7- membered heterocycle.

15. A compound as claimed in Claim 11, pharmaceutically acceptable salt, or solvate thereof, wherein A ring is a ring represented by (A-1); Z=NR^{26}, and R^{25} and R^{26} taken together with the neighboring atom may form an optionally substituted 5- to 7- membered heterocycle.

16. A compound as claimed in Claim 11, pharmaceutically acceptable salt, or solvate thereof, wherein A ring is a ring represented by (A-2); one of R^{27} to R^{30} is optionally substituted C_1-C_{10} alkyl and the others are hydrogens.

17. A compound as claimed in Claim 11, pharmaceutically acceptable salt, or solvate thereof, wherein A ring is a ring represented by (A-2); one of ($R^{27}$and R^{29}) and (R^{30} and R^{31}), taken together with the neighboring atom, may form an optionally substituted 5- to 7- membered carbocyle or optionally substituted 5- to 7- membered heterocycle.

18. A compound as claimed in Claim 11, pharmaceutically acceptable salt, or solvate thereof, wherein A ring is a ring represented by (A-2); Z=NR^{31}, and R^{30} and R^{31} taken together with the neighboring atom may form an optionally substituted 5- to 7- membered heterocycle.

19. A compound as claimed in Claim 11, pharmaceutically acceptable salt, or solvate thereof, wherein A ring is a ring represented by (A-3); one of R^{32} to R^{39} is optionally substituted C_1-C_{10} alkyl and the others are hydrogens.

20. A compound as claimed in Claim 11, pharmaceutically acceptable salt, or solvate thereof, wherein A ring is a ring represented by (A-3); one of (R^{32}andR^{34}),(R^{35}andR^{36}),(R^{37}andR^{38}),and(R^{39}andR^{40}), taken together with the neighboring atom, may form an optionally substituted 5- to 7- membered carbocyle or optionally substituted 5- to 7- membered heterocycle.

21. A compound as claimed in Claim 11, pharmaceutically acceptable salt, or solvate thereof, wherein A ring is a ring represented by (A-3); Z=NR^{40}, and R^{39} and R^{40} taken together with the neighboring atom may form an optionally substituted 5- to 7- membered heterocycle.

22. A compound as claimed in Claim 6, pharmaceutically acceptable salt, or solvate thereof, wherein R^X is hydrogen; R^{14} is hydrogen; R^3 is hydrogen; m is 1 to 3 and at least one of Rs is halogen; A ring is a ring described in Claim 11.

23. A compound as claimed in Claim 6, pharmaceutically acceptable salt, or solvate thereof, wherein R^X is hydrogen; R^{14} is hydrogen; R^3 is hydrogen; m is 0, or 1 to 3 and at least one of R is halogen; A ring is a ring described in Claim 11; R^{20} to R^{40} are each independently hydrogen or substituted C_1-C_{10} alkyl, or any two groups of R^{20} to R^{40}, which bonds to the same carbon atom, taken together with the carbon atom, may form an optionally substituted 3- to 7-membered carbocyle or optionally substituted 3- to 7- membered heterocycle, or each combination of (R^{20} and R^{22}), (R^{23} and R^{24}), (R^{25} and R^{26}), (R^{27} and R^{29}), (R^{30} and R^{31}), (R^{32} and R^{34}), (R^{35} and R^{36}), (R^{37} and R^{38}), and (R^{39}andR^{40}), taken together with the neighboring carbon atom, may form an optionally substituted 5- to 7- membered carbocyle or optionally substituted 5- to 7- membered heterocycle.

24. A compound of the formula:



(I-11)

wherein,

D ring is optionally substituted heterocycle;

R^1 is hydrogen or C_1-C_{10} alkyl;

X is a single bond, a heteroatom group selected from O, S, SO, SO_2 and NH, or C_1-C_6 alkylene or C_2-C_6 alkenylene each may be intervened by the heteroatom group;

R^2 is optionally substituted aryl;

R^3 is hydrogen, halogen, hydroxy, optionally substituted C_1-C_{10} alkyl, optionally substituted C_3-C_8 cycloalkyl, optionally substituted C_2-C_8 alkenyl, optionally substituted C_1-C_{10} alkoxy, optionally substituted C_2-C_8 alkenyloxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterocyclic group, optionally substituted heterocycleoxy or optionally substituted amino;

or a pharmaceutically acceptable salt, or solvate thereof

and wherein:

(a) a group which is optionally substituted, other than optionally substituted amino, optionally substituted carbamoyl or optionally substituted phosphoric acid, is a group which is unsubstituted or substituted at any position by 1 to 4 substituents B, which are the same or different, B being selected from hydroxy, carboxy, halogen, halo C_1-C_{10} alkyl, halo C_1-C_{10} alkoxy, C_1-C_{10} alkyl, C_2-C_8 alkenyl, ethynyl, C_3-C_8 cycloalkyl, cycloalkenyl, C_1-C_{10} alkoxy C_2-C_8 alkenyloxy, C_1-C_{10} alkoxycarbonyl, nitro, nitroso, optionally substituted amino, acylamino, aralkylamino, hydroxyamino, azido, aryl, aralkyl, cyano, isocyano, isocyanate, thiocyanate, isothiocyanate, mercapt, alkylthio, alkylsulfonyl, optionally substituted alkylsulfonylamino, optionally substituted carbamoyl, sulfamoyl, acyl, formyloxy, haloformyl, oxal, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, sulfino, sulfo, sulfoamino, hydrazino, azido, ureido, amizino, quanidino, phthalimide, oxo, phosphoric acid residue, C_1-C_{10} alkyl which is substituted with a phosphoric acid residue and may be intervened with a heteroatom group(s), aryl substituted with a phosphoric acid residue, aralkyl substituted with a phosphoric acid residue, hydroxyl C_1-C_{10} alkyl, carboxy, halogen, halo C_1-C_{10} alkyl, halo C_1-C_{10} alkoxy, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, optionally substituted amino, oxo and phosphoric acid residue;

(b) "optionally substituted amino" or "optionally substituted carbamoyl" means an amino or carbamoyl group which is unsubstituted or substituted by a group selected from mono- or di- C_1-C_{10} alkyl, C_1-C_{10} alkylcarbonyl, C_1-C_{10} alkylsulfonyl, optionally substituted C_1-C_{10} alkyl, carbamoylalkyl, mono- or di- C_1-C_{10} alkylcarbamoyl, C_1-C_{10} alkyl, hydroxyl C_1-C_{10} alkyl, heterocycle C_1-C_{10} alkyl, C_1-C_{10} alkoxycarbonyl C_1-C_{10} alkyl, mono- or di- C_1-C_{10} alkylamino C_1-C_{10} alkyl, C_1-C_{10} alkoxy C_1-C_{10} alkyl, acyl, C_1-C_{10} alkoxy C_1-C_{10} alkylcarbonyl, C_1-C_{10} alkylcarbamoyl C_1-C_{10} alkylcarbonyl, C_1-C_{10} alkoxycarbonylacetyl, optionally substituted arylcarbonyl, optionally substituted aralkyl, hydroxy, optionally substituted C_1-C_{10} alkylsulfonyl, C_1-C_{10} alkyl, or arylsulfonyl optionally substituted with halogen, C_3-C_8 cycloalkyl, aryl optionally substituted with C_1-C_{10} alkyl, C_1-C_{10} alkylaminosulfonyl, C_1-C_{10} alkylaminocarbonyl, C_1-C_{10} alkoxycarbonyl, C_3-C_8 cycloalkylcarbonyl, optionally substituted sulfamoyl, C_1-C_{10} alkylcarbonylamino, heterocycle, and optionally substituted amino, and wherein, as to the amino of "optionally substituted amino", "optionally substituted carbamoyl", or "optionally substituted carbamoylcarbonyl", two substituents on the amino together with the neighboring N atom may form an N-containing heterocycle which optionally contains S and/or O in the ring and is optionally substituted with oxo or hydroxy.

25. A compound selected from:

(3*R*,11a*S*)-*N*-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;

(4a*R*,13a*S*)-*N*-[(2,4-Difluorophenyl)methyl]-10-hydroxy-9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydro-1*H*-pyrido[1,2-*a*]pyrrolo[1',2':3,4]imidazo[1,2-*d*]pyrazine-8-carboxamide;

(3a*S*,13a*S*)-*N*-[(2,4-Difluorophenyl)methyl]-8-hydroxy-7,9-dioxo-1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1',2':4,5]pyrazino[1,2-*a*]pyrrolo[1,2-*c*]pyrimidine-10-carboxamide;

(4a*S*,13a*R*)-*N*-[(2,4-Difluorophenyl)methyl]-10-hydroxy-9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydro-1*H*-pyrido[1,2-*a*]pyrrolo[1',2':3,4]imidazo[1,2-*d*]pyrazine-8-carboxamide;

(4a*S*,13a*R*)-*N*-[(4-Fluorophenyl)methyl]-10-hydroxy-9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydro-1*H*-pyrido[1,2-*a*]pyrrolo[1',2':3,4]imidazo[1,2-*d*]pyrazine-8-carboxamide;

(3*S*,11a*R*)-*N*-[(2,4-Difluorophenyl)methyl]-6-hydroxy-5,7-dioxo-3-(phenylmethyl)-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;
(3a*S*,13a*S*)-*N*-[(4-Fluorophenyl)methyl]-8-hydroxy-7,9-dioxo-1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1',2':4,5]pyrazino[1,2-*a*]pyrrolo[1,2-*c*]pyrimidine-10-carboxamide;

(3*S*,11a*R*)-*N*-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-[(1*S*)-1-methylpropyl]-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;
(3*S*,11a*R*)-*N*-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;

(3*S*,11a*R*)-*N*-[(4-Fluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;

(3*S*,11a*R*)-*N*-[(2,4-Difluorophenyl)methyl]-3-(1,1-dimethylethyl)-6-hydroxy-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;

(3*S*,11a*R*)-3-(1,1-Dimethylethyl)-*N*-[(4-fluorophenyl)methyl]-6-hydroxy-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;

(3*S*,11a*R*)-*N*-[(2,4-Difluorophenyl)methyl]-6-hydroxy-5,7-dioxo-3-phenyl-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;

(3*S*,11a*R*)-*N*-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-(hydroxymethyl)-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;

(2*S*,3*R*)-*N*-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2-phenyl-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;

(3*R*,11a*S*)-*N*-[(2,4-Difluorophenyl)methyl]-6-hydroxy-5,7-dioxo-3-(phenylmethyl)-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;
(3*R*,11a*S*)-*N*-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-(2-methylpropyl)-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;

(5a*R*,14a*R*)-*N*-[(2,4-Difluorophenyl)methyl]-11-hydroxy-10,12-dioxo-1,2,3,4,5a,6,10,12,14,14a-decahydropyrido[1,2-*a*]pyrido[1',2':3,4]imidazo[1,2-*d*]pyrazine-9-carboxamide;

(2*S*,3*S*)-*N*-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-[(methyloxy)methyl]-5,7-dioxo-2-phenyl-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;

(3*S*,11a*R*)-3-(Cyclohexylmethyl)-*N*-[(2,4-difluorophenyl)methyl]-6-hydroxy-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;

(3*S*,11a*R*)-*N*-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-(1-methylethyl)-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;

(5a*R*,14a*S*)-*N*-[(2,4-Difluorophenyl)methyl]-12-hydroxy-11,13-dioxo-5a,6a,7,11,13,14a-hexahydro-5*H*-indeno[1',2':4,5][1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-10-carboxamide;

(2*S*,3*R*,11a*S*)-*N*-[(2,4-Difluorophenyl)methyl]-6-hydroxy-5,7-dioxo-2,3-diphenyl-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;

(2*S*,3*R*,11a*R*)-*N*-[(2,4-difluorophenyl)methyl]-6-hydroxy-5,7-dioxo-2,3-diphenyl-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;

(3*R*,11a*S*)-*N*-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-(1-methylethyl)-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;

(3*S*,11a*R*)-*N*-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-[2-(methylthio)ethyl]-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;

(3*S*,11a*R*)-*N*-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-[2-(methylsulfonyl)ethyl]-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;

(3*S*,11a*R*)-*N*-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-(1*H*-indol-3-ylmethyl)-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;

(4*R*,12a*R*)-*N*-[(4-fluorophenyl)methyl]-7-hydroxy-4-methyl-1-(2-methylpropyl)-6,8-dioxo-1,2,3,4,6,8,12,12a-octahydropyrido[1',2':4,5]pyrazino[1,2-*a*]pyrimidine-9-carboxamide;

(4*R*,12a*R*)-*N*-[(4-Fluorophenyl)methyl]-7-hydroxy-4-methyl-1-(1-methylethyl)-6,8-dioxo-1,2,3,4,6,8,12,12a-octahydropyrido[1',2':4,5]pyrazino[1,2-*a*]pyrimidine-9-carboxamide;

(4*S*,12a*S*)-*N*-[(2,4-Difluorophenyl)methyl]-7-hydroxy-4-methyl-1-(2-methylpropyl)-6,8-dioxo-1,2,3,4,6,8,12,12a-octahydropyrido[1',2':4,5]pyrazino[1,2-*a*]pyrimidine-9-carboxamide;

(4*S*,12a*S*)-1-(Cyclopropylmethyl)-*N*-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-1,2,3,4,6,8,12,12a-octahydropyrido[1',2':4,5]pyrazino[1,2-*a*]pyrimidine-9-carboxamide;

(4*S*,12a*S*)-*N*-[(2,4-Difluorophenyl)methyl]-1-(2-furanylmethyl)-7-hydroxy-4-methyl-6,8-dioxo-1,2,3,4,6,8,12,12a-octahydropyrido[1',2':4,5]pyrazino[1,2-*a*]pyrimidine-9-carboxamide;

(4*S*,12a*S*)-*N*-[(2,4-Difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-1-(1,3-thiazol-2-ylmethyl)-1,2,3,4,6,8,12,12a-octahydropyrido[1',2':4,5]pyrazino[1,2-*a*]pyrimidine-9-carboxamide;

(4a*R*,6a*R*,14a*S*)-*N*-[(2,4-Difluorophenyl)methyl]-12-hydroxy-11,13-dioxo-1,3,4,4a,5,6a,7,11,13,14a-decahydro-2*H*-pyrido[1',2':4,5]pyrazino[1,2-*a*][3,1]benzoxazine-10-carboxamide;

(4a*R*,6a*R*,14a*S*)-*N*-[(4-Fluorophenyl)methyl]-12-hydroxy-11,13-dioxo-1,3,4,4a,5,6a,7,11,13,14a-decahydro-2*H*-pyrido[1',2':4,5]pyrazino[1,2-*a*][3,1]benzoxazine-10-carboxamide;

(3*S*,4a*R*,6a*R*,14a*S*)-*N*-[(2,4-Difluorophenyl)methyl]-12-hydroxy-11,13-dioxo-3-phenyl-1,3,4,4a,5,6a,7,11,13,14a-decahydro-2*H*-pyrido[1',2':4,5]pyrazino[1,2-*a*][3,1]benzoxazine-10-carboxamide;

(4aS,6aS,14aS)-N-[(2,4-Difluorophenyl)methyl]-12-hydroxy-6-(2-methylpropyl)-11,13-dioxo-1,2,3,4,4a,5,6,6a,7,11,13,14a-dodecahydropyrido[1',2':4,5]pyrazino[1,2-a]quinazoline-10-carboxamide;

(6aR,7aS,11aS)-N-[(2,4-Difluorophenyl)methyl]-1-hydroxy-2,13-dioxo-2,6a,7,7a,8,9,10,11,11a,13-decahydro-6H-pyrido[1',2':4,5]pyrazino[1,2-a]benzimidazole-3-carboxamide;

(6aS,7aS,11aS)-N-[(2,4-Difluorophenyl)methyl]-1-hydroxy-2,13-dioxo-2,6a,7,7a,8,9,10,11,11a,13-decahydro-6H-pyrido[1',2':4,5]pyrazino[1,2-a]benzimidazole-3-carboxamide;

(5aS,14aS)-N-[(2,4-Difluorophenyl)methyl]-11-hydroxy-10,12-dioxo-1,2,3,4,5a,6,10,12,14,14a-decahydropyrido[1,2-a]pyrido[1',2':3,4]imidazo[1,2-d]pyrazine-9-carboxamide;

(4aR,14aR)-N-[(2,4-Difluorophenyl)methyl]-9-hydroxy-8,10-dioxo-2,3,4,4a,5,6,8,10,14,14a-decahydro-1H-pyrido[1,2-c]pyrido[1',2':4,5]pyrazino[1,2-a]pyrimidine-11-carboxamide;

(4*R*,12a*R*)-*N*-[(2,4-Difluorophenyl)methyl]-7-hydroxy-4-methyl-1-(3-methylbutyl)-6,8-dioxo-1,2,3,4,6,8,12,12a-octahydropyrido[1',2':4,5]pyrazino[1,2-*a*]pyrimidine-9-carboxamide;
(4*S*,12a*S*)-*N*-[(2,4-Difluorophenyl)methyl]-7-hydroxy-4-methyl-1-(1-methylethyl)-6,8-dioxo-1,2,3,4,6,8,12,12a-octahydropyrido[1',2':4,5]pyrazino[1,2-*a*]pyrimidine-9-carboxamide;

(4*S*,12a*S*)-*N*-[(2,4-Difluorophenyl)methyl]-7-hydroxy-4-methyl-1-(3-methylbutyl)-6,8-dioxo-1,2,3,4,6,8,12,12a-octahydropyrido[1',2':4,5]pyrazino[1,2-*a*]pyrimidine-9-carboxamide;

(4*S*,12a*S*)-*N*-[(2,4-Difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-1-(3-pyridinylmethyl)-1,2,3,4,6,8,12,12a-octahydropyrido[1',2':4,5]pyrazino[1,2-*a*]pyrimidine-9-carboxamide;

(4*S*,12a*S*)-1-Cyclopropyl-*N*-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-1,2,3,4,6,8,12,12a-octahydropyrido[1',2':4,5]pyrazino[1,2-*a*]pyrimidine-9-carboxamide;

(4*S*,12a*S*)-*N*-[(2,4-Difluorophenyl)methyl]-7-hydroxy-4-methyl-1-[2-(methyloxy)ethyl]-6,8-dioxo-1,2,3,4,6,8,12,12a-octahydropyrido[1',2':4,5]pyrazino[1,2-*a*]pyrimidine-9-carboxamide;

(3aS,5aS,13aS)-N-[(2,4-Difluorophenyl)methyl]-11-hydroxy-5-(2-methylpropyl)-10,12-dioxo-2,3,3a,4,5,5a,6,10,12,13a-decahydro-1H-cyclopenta[e]pyrido[1',2':4,5]pyrazino[1,2-a]pyrimidine-9-carboxamide;

(3*R*,11a*S*)-*N*-[(2,4-Difluorophenyl)methyl]-3-ethyl-6-hydroxy-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;

(4aS,6aS,14aS)-N-[(2,4-Difluorophenyl)methyl]-12-hydroxy-6-[2-(4-morpholinyl)ethyl]-11,13-dioxo-1,2,3,4,4a,5,6,6a,7,11,13,14a-dodecahydropyrido[1',2':4,5]pyrazino[1,2-a]quinazoline-10-carboxamide;
(3aR,5aR,13aS)-N-[(2,4-Difluorophenyl)methyl]-11-hydroxy-10,12-dioxo-1,2,3,3a,4,5a,6,10,12,13a-decahydrocyclopenta[d]pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide;

(4aS,6aS,14aS)-N-[(2,4-Difluorophenyl)methyl]-12-hydroxy-6-methyl-11,13-dioxo-1,2,3,4,4a,5,6,6a,7,11,13,14a-dodecahydropyrido[1',2':4,5]pyrazino[1,2-a]quinazoline-10-carboxamide;

(4aS,6aS,14aS)-N-[(2,4-Difluorophenyl)methyl]-12-hydroxy-6-[2-(methyloxy)ethyl]-11,13-dioxo-1,2,3,4,4a,5,6,6a,7,11,13,14a-dodecahydropyrido[1',2':4,5]pyrazino[1,2-a]quinazoline-10-carboxamide;

(4aS,6aS,14aS)-6-[2-(Acetylamino)ethyl]-N-[(2,4-difluorophenyl)methyl]-12-hydroxy-11,13-dioxo-1,2,3,4,4a,5,6,6a,7,11,13,14a-dodecahydropyrido[1',2':4,5]pyrazino[1,2-a]quinazoline-10-carboxamide;

(3*S*,11a*R*)-*N*-[(2,4-Difluorophenyl)methyl]-3-ethyl-6-hydroxy-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;

(3*S*,11a*R*)-3-Butyl-*N*-[(2,4-difluorophenyl)methyl]-6-hydroxy-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;

(3*S*,11a*R*)-*N*-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-[(4-hydroxyphenyl)methyl]-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;
(4S,12aS)-1-Cyclobutyl-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-1,2,3,4,6,8,12,12a-octahydropyrido[1',2':4,5]pyrazino[1,2-a]pyrimidine-9-carboxamide;

(4*S*,12a*S*)-*N*-[(2,4-Difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-1-(tetrahydro-2*H*-thiopyran-4-yl)-1,2,3,4,6,8,12,12a-octahydropyrido[1',2':4,5]pyrazino[1,2-*a*]pyrimidine-9-carboxamide;

(4*S*,12a*S*)-*N*-[(2,4-Difluorophenyl)methyl]-7-hydroxy-1,4-bis(2-methylpropyl)-6,8-dioxo-1,2,3,4,6,8,12,12a-octahydropyrido[1',2':4,5]pyrazino[1,2-*a*]pyrimidine-9-carboxamide;

(4aS,6aS,14aS)-N-[(2,4-Difluorophenyl)methyl]-12-hydroxy-6-(2-hydroxyethyl)-11,13-dioxo-1,2,3,4,4a,5,6,6a,7,11,13,14a-dodecahydropyrido[1',2':4,5]pyrazino[1,2-a]quinazoline-10-carboxamide;

(4aS,6aS,14aS)-6-Cyclopropyl-N-[(2,4-difluorophenyl)methyl]-12-hydroxy-11,13-dioxo-1,2,3,4,4a,5,6,6a,7,11,13,14a-dodecahydropyrido[1',2':4,5]pyrazino[1,2-a]quinazoline-10-carboxamide;

(4aS,6aS,14aS)-N-[(2,4-Difluorophenyl)methyl]-12-hydroxy-11,13-dioxo-6-[2-(1-pyrrolidinyl)ethyl]-1,2,3,4,4a,5,6,6a,7,11,13,14a-dodecahydropyrido[1',2':4,5]pyrazino[1,2-a]quinazoline-10-carboxamide;
(4aS,14aS)-N-[(2,4-Difluorophenyl)methyl]-9-hydroxy-8,10-dioxo-2,3,4,4a,5,6,8,10,14,14a-decahydro-1H-pyrido[1,2-c]pyrido[1',2':4,5]pyrazino[1,2-a]pyrimidine-11-carboxamide;

(4S,12aS)-N-[(4-Fluorophenyl)methyl]-7-hydroxy-4-methyl-1-[2-(methyloxy)ethyl]-6,8-dioxo-1,2,3,4,6,8,12,12a-octahydropyrido[1',2':4,5]pyrazino[1,2-a]pyrimidine-9-carboxamide;

(4S,12aS)-1-Cyclobutyl-N-[(4-fluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-1,2,3,4,6,8,12,12a-octahydropyrido[1',2':4,5]pyrazino[1,2-a]pyrimidine-9-carboxamide;

(4S,12aS)-N-[(4-Fluorophenyl)methyl]-7-hydroxy-4-methyl-1-(2-methylpropyl)-6,8-dioxo-1,2,3,4,6,8,12,12a-octahydropyrido[1',2':4,5]pyrazino[1,2-a]pyrimidine-9-carboxamide;

(4S,12aS)-N-[(4-Fluorophenyl)methyl]-7-hydroxy-1,4-dimethyl-6,8-dioxo-1,2,3,4,6,8,12,12a-octahydropyrido[1',2':4,5]pyrazino[1,2-a]pyrimidine-9-carboxamide;

(4*S*,12a*S*)-*N*-[(4-Fluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-1-(tetrahydro-2*H*-thiopyran-4-yl)-1,2,3,4,6,8,12,12a-octahydropyrido[1',2':4,5]pyrazino[1,2-*a*]pyrimidine-9-carboxamide;

(4*S*,12a*S*)-*N*-[(2,4-Difluorophenyl)methyl]-7-hydroxy-1,4-dimethyl-6,8-dioxo-1,2,3,4,6,8,12,12a-octahydropyrido[1',2':4,5]pyrazino[1,2-*a*]pyrimidine-9-carboxamide;

(4*S*,12a*S*)-*N*-[(4-Fluorophenyl)methyl]-7-hydroxy-4-methyl-1-(1-methylethyl)-6,8-dioxo-1,2,3,4,6,8,12,12a-octahydropyrido[1',2':4,5]pyrazino[1,2-*a*]pyrimidine-9-carboxamide;

(4*S*,12a*S*)-*N*-[(4-Fluorophenyl)methyl]-7-hydroxy-1,4-bis(2-methylpropyl)-6,8-dioxo-1,2,3,4,6,8,12,12a-octahydropyrido[1',2':4,5]pyrazino[1,2-*a*]pyrimidine-9-carboxamide;

enantiomers thereof; diastereomers thereof; mixtures of enantiomers thereof; mixtures of diastereomers thereof; mixtures of enantiomers and diastereomers thereof; and pharmaceutically acceptable salts thereof.

26. A compound selected from:
(4a*S*,13a*R*)-*N*-[(2,4-Difluorophenyl)methyl]-10-hydroxy-9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydro-1*H*-pyrido[1,2-*a*]pyrrolo[1',2':3,4]imidazo[1,2-*d*]pyrazine-8-carboxamide;

(4a*S*,13a*R*)-*N*-[(4-Fluorophenyl)methyl]-10-hydroxy-9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydro-1*H*-pyrido[1,2-*a*]pyrrolo[1',2':3,4]imidazo[1,2-*d*]pyrazine-8-carboxamide;

(3*S*,11a*R*)-*N*-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-[(1*S*)-1-methylpropyl]-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;

(3*S*,11a*R*)-*N*-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;

(3*S*,11a*R*)-*N*-[(4-Fluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide;

(4*S*,12a*S*)-*N*-[(2,4-Difluorophenyl)methyl]-7-hydroxy-4-methyl-1-(2-methylpropyl)-6,8-dioxo-1,2,3,4,6,8,12,12a-octahydropyrido[1',2':4,5]pyrazino[1,2-*a*]pyrimidine-9-carboxamide;

(4*S*,12a*S*)-1-(Cyclopropylmethyl)-*N*-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-1,2,3,4,6,8,12,12a-octahydropyrido[1',2':4,5]pyrazino[1,2-*a*]pyrimidine-9-carboxamide;

(4a*R*,6a*R*,14a*S*)-*N*-[(2,4-Difluorophenyl)methyl]-12-hydroxy-11,13-dioxo-1,3,4,4a,5,6a,7,11,13,14a-decahydro-2*H*-pyrido[1',2':4,5]pyrazino[1,2-*a*][3,1]benzoxazine-10-carboxamide;

(4a*R*,6a*R*,14a*S*)-*N*-[(4-Fluorophenyl)methyl]-12-hydroxy-11,13-dioxo-1,3,4,4a,5,6a,7,11,13,14a-decahydro-2*H*-pyrido[1',2':4,5]pyrazino[1,2-*a*][3,1]benzoxazine-10-carboxamide;

(4S,9aR)-5-Hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a, 8a-diaza-anthracene-7-carboxylic acid 2,4,-difluoro-benzylamide;

(4R,9aS)-5-Hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a, 8a-diaza-anthracene-7-carboxylic acid 2,4,-difluoro-benzylamide;

(2R,9aS)-5-Hydroxy-2-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a, 8a-diaza-anthracene-7-carboxylic acid 4-fluoro-benzylamide;

enantiomers thereof; diastereomers thereof; mixtures of enantiomers thereof; mixtures of diastereomers thereof; mixtures of enantiomers and diastereomers thereof; and pharmaceutically acceptable salts thereof.

27. A compound as claimed in claims 25 or 26 wherein the pharmaceutically acceptable salt is a sodium salt.

28. A pharmaceutical composition comprising a compound as claimed in any one of Claims 1 to 27, or a pharmaceutically acceptable salt, or solvate thereof.

29. A pharmaceutical composition as claimed in Claim 28, which is an anti-HIV agent.

30. A process for the preparation of a compound of formula (I-20a)



(I-20a)

wherein R^e is one or two halogen; R^z is C_{1-8}alkyl, C_{6-14}arylC_{1-8}alkyl, C_{6-14}aryl, or alkoxy; and P^1 is C_{6-14}arylC_{1-8}alkyl;

comprising condensing a compound of the formula



wherein R^e is one or two halogen; R^{50} is C_{1-8}alkyl; and P^1 is C_{6-14}arylC_{1-8}alkyl;
with a compound of the formula



wherein R^z is C_{1-8}alkyl, C_{6-14}arylC_{1-8}alkyl, C_{6-14}aryl, or alkoxy;
to form a compound of formula (I-20a).

31. A process for the preparation of a compound of formula (I-20b)



(I-20b)

wherein R^e is one or two halogen; R^z is C_{1-8}alkyl, C_{6-14}arylC_{1-8}alkyl, C_{6-14}aryl, or alkoxy; and P^1 is C_{6-14}arylC_{1-8}alkyl;

comprising condensing a compound of the formula



wherein R^e is one or two halogen; R^{50} is C_{1-8}alkyl; and P^1 is C_{6-14}arylC_{1-8}alkyl;

with a compound of the formula



wherein R^z is C_{1-8}alkyl, C_{6-14}arylC_{1-8}alkyl, C_{6-14}aryl, or alkoxy;

to form a compound of formula (I-20b).

32. A process for the preparation of a compound of formula (I-21a)



(I-21a)

wherein R^e is one or two halogen; and P^1 is C_{6-14}arylC_{1-8}alkyl;

comprising condensing a compound of the formula



wherein R^e is one or two halogen; R^{50} is C_{1-8}alkyl; and P^1 is C_{6-14}arylC_{1-8}alkyl;

with a compound of the formula



to form a compound of formula (I-21a).

33. A process for the preparation of a compound of formula (I-21b)



(I-21b)

wherein R^e is one or two halogen; and P^1 is C_{6-14}arylC_{1-8}alkyl;

comprising condensing a compound of the formula



wherein R^e is one or two halogen; R^{50} is C_{1-8}alkyl; and P^1 is C_{6-14}arylC_{1-8}alkyl;

with a compound of the formula



to form a compound of formula (I-21b).

34. A process for the preparation of a compound of formula (I-22a)



(I-22a)

wherein R^e is one or two halogen; and P^1 is C_{6-14}arylC_{1-8}alkyl;

comprising condensing a compound of the formula:



wherein R^e is one or two halogen; R^{50} is C_{1-8}alkyl; and P^1 is C_{6-14}arylC_{1-8}alkyl;
with a compound of the formula



to form a compound of formula (I-22a).

35. A process for the preparation of a compound of formula (I-22b)



(I-22b)

wherein R^e is one or two halogen; and P^1 is C_{6-14}arylC_{1-8}alkyl;
comprising condensing a compound of the formula



wherein R^e is one or two halogen; R^{50} is C_{1-8}alkyl; and P^1 is C_{6-14}arylC_{1-8}alkyl;
with a compound of the formula



to form a compound of formula (I-22b).

36. A process for the preparation of a compound of formula (I-23a)



(I-23a)

wherein R^e is one or two halogen; and P^1 is $C_{6-14}arylC_{1-8}alkyl$;
comprising condensing a compound of the formula



wherein R^e is one or two halogen; R^{50} is $C_{1-8}alkyl$; and P^1 is $C_{6-14}arylC_{1-8}alkyl$;
with a compound of the formula



to form a compound of formula (I-23a).

37. A process for the preparation of a compound of formula (I-23b)



(I-23b)

wherein R^e is one or two halogen; and P^1 is $C_{6-14}arylC_{1-8}alkyl$;
comprising condensing a compound of the formula



wherein R^e is one or two halogen; R^{50} is $C_{1-8}alkyl$; and P^1 is $C_{6-14}arylC_{1-8}alkyl$;
with a compound of the formula



to form a compound of formula (I-23b).

38. A process for the preparation of a compound of formula (I-24a)



(I-24a)

wherein R^e is one or two halogen; R^{z1} is hydrogen, C_{3-6}cycloalkyl, heterocycle, or C_{1-8}alkyl optionally substituted with hydroxy, C_{3-6}cycloalkyl, alkoxy, heterocycle, heteroaryl, C_{6-14}aryl, or amino, wherein said amino may be optionally substituted with $-C(O)C_{1-8}$alkyl or C_{1-8}alkyl; and P^1 is C_{6-14}arylC_{1-8}alkyl;

comprising condensing a compound of the formula



wherein R^e is one or two halogen; R^{50} is C_{1-8}alkyl; and P^1 is C_{6-14}arylC_{1-8}alkyl;
with a compound of the formula



wherein R^z is C_{1-8}alkyl; R^{z1} is hydrogen, C_{3-6}cycloalkyl, , heterocycle, or C_{1-8}alkyl optionally substituted with hydroxy, C_{3-6}cycloalkyl, alkoxy, heterocycle, heteroaryl, C_{6-14}aryl, or amino, wherein said amino may be optionally substituted with $-C(O)C_{1-8}$alkyl or C_{1-8}alkyl;

to form a compound of the formula (I-24a).

39. A process for the preparation of a compound of formula (I-24b)



(I-24b)

wherein R^e is one or two halogen; R^{z1} is hydrogen, C_{3-6}cycloalkyl, heterocycle, or C_{1-8}alkyl optionally substituted with hydroxy, C_{3-6}cycloalkyl, alkoxy, heterocycle, heteroaryl, C_{6-14}aryl, or amino, wherein said amino may be optionally substituted with $-C(O)C_{1-8}$alkyl or C_{1-8}alkyl; and P^1 is C_{6-14}arylC_{1-8}alkyl;

comprising condensing a compound of the formula



wherein R^e is one or two halogen; R^{50} is C_{1-8}alkyl; and P^1 is C_{6-14}arylC_{1-8}alkyl;
with a compound of the formula



wherein R^z is C_{1-8}alkyl; R^{z1} is hydrogen, C_{3-6}cycloalkyl, heterocycle, or C_{1-8}alkyl optionally substituted with hydroxy, C_{3-6}cycloalkyl, alkoxy, heterocycle, heteroaryl, C_{6-14}aryl, or amino, wherein said amino may be optionally substituted with $-C(O)C_{1-8}$alkyl or C_{1-8}alkyl;
to form a compound of the formula (I-24b).

40. A process for the preparation of a racemic compound of formula (I-25)



(I-25)

wherein R^e is one or two halogen; R^{z1} is hydrogen, C_{3-6}cycloalkyl, heterocycle, or C_{1-8}alkyl optionally substituted with hydroxy, C_{3-6}cycloalkyl, alkoxy, heterocycle, heteroaryl, C_{6-14}aryl, or amino, wherein said amino may be optionally substituted with $-C(O)C_{1-8}$alkyl or C_{1-8}alkyl; and P^1 is C_{6-14}arylC_{1-8}alkyl;

comprising condensing a compound of the formula



wherein R^e is one or two halogen; R^{50} is C_{1-8}alkyl; and P^1 is C_{6-14}arylC_{1-8}alkyl;
with a racemic compound of the formula



wherein R^{z1} is hydrogen, C_{3-6}cycloalkyl, heterocycle, or C_{1-8}alkyl optionally substituted with hydroxy, C_{3-6}cycloalkyl, alkoxy, heterocycle, heteroaryl, C_{6-14}aryl, or amino, wherein said amino may be optionally substituted with $-C(O)C_{1-8}$alkyl or C_{1-8}alkyl;

to form a racemic compound of the formula (I-25).

41. A process for the preparation of a racemic compound of formula (I-26)



(I-26)

wherein R^e is one or two halogen; R^{z1} is hydrogen, C_{3-6}cycloalkyl, heterocycle, or C_{1-8}alkyl optionally substituted with hydroxy, C_{3-6}cycloalkyl, alkoxy, heterocycle, heteroaryl, C_{6-14}aryl, or amino, wherein said amino may be optionally substituted with $-C(O)C_{1-8}$alkyl or C_{1-8}alkyl; and P^1 is C_{6-14}arylC_{1-8}alkyl;

comprising condensing a compound of the formula



wherein R^e is one or two halogen; R^{50} is C_{1-8}alkyl; and P^1 is C_{6-14}arylC_{1-8}alkyl;
with a racemic compound of the formula



wherein R^{z1} is hydrogen, C_{3-6}cycloalkyl, heterocycle, or C_{1-8}alkyl optionally substituted with hydroxy, C_{3-6}cycloalkyl, alkoxy, heterocycle, heteroaryl, C_{6-14}aryl, or amino, wherein said amino may be optionally substituted with $-C(O)C_{1-8}$alkyl or C_{1-8}alkyl;
to form a racemic compound of formula (I-26).

42. A process for the preparation of a racemic compound of formula (I-27)



(I-27)

wherein R^e is halogen; and P^1 is C_{6-14}arylC_{1-8}alkyl;
comprising condensing a compound of the formula



wherein R^e is one or two halogen; R^{50} is C_{1-8}alkyl; and P^1 is C_{6-14}arylC_{1-8}alkyl;
with a racemic compound of the formula



to form a racemic compound of formula (I-27).



to form a racemic compound of formula (I-27).

43. A compound as claimed in any of claims 1 to 27 for use in a method of treatment of the human or animal body by therapy.

44. A compound as claimed in any of claims 1 to 27 for use in the treatment or prophylaxis of an HIV infection.

45. A compound of formula (I-20a) as defined in Claim 30, formula (I-20b) as defined in Claim 31, formula (I-21a) as defined in Claim 32, formula (I-21b) as defined in Claim 33, formula (I-22a) as defined in Claim 34, formula (I-22b) as defined in Claim 35, formula (I-23a) as defined in Claim 36, formula (I-23b) as defined in Claim 37, formula (I-24a) as defined in Claim 38, formula (I-24b) as defined in Claim 39, formula (I-25) as defined in Claim 40, formula (I-26) as defined in Claim 41, or formula (I-27) as defined in Claim 42, or a pharmaceutically acceptable salt thereof.

46. A compound as defined in Claim 45, or a pharmaceutically acceptable salt thereof, wherein each P^1 is hydrogen.

47. A pharmaceutical composition as claimed in claim 28 wherein said composition comprises at least one additional therapeutic agent selected from reverse transcriptase inhibitors and protease inhibitors.

48. (4R,9aS)-5-Hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a, 8a-diaza-anthracene-7-carboxylic acid 2,4,-difluoro-benzylamide or a pharmaceutically acceptable salt thereof.

49. A compound of the formula



or a pharmaceuticlly acceptable salt thereof.

50. A compound of the formula



or a pharmaceutically acceptable salt thereof.

51. A product prepared by the process as claimed in any one of claims 30 to 42.

Dated this 10th day of October, 2007.

(DR. I. S. BHATTACHARYA)
of D. P. AHUJA & CO.
APPLICANTS' AGENT
(Reg. No. IN/PA-270)